MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Balance Sheets Overview

Current Ratio
1451.89%
Quick Ratio
1451.89%
Cash Ratio
1364.48%
Debt to Asset Ratio
12.51%
Unit: Thousand (K) dollars
Assets Breakdown
    • Other assets
    • Intangible assets
    • Operating lease right-of-use ass...
    • Short-term investments
Liabilities Breakdown
    • Accumulated deficit
    • Additional paid in capital
    • Series c preferred stock, 0.001 ...
    • Others
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
115,981
18,163
5,809
6,452
Short-term investments
0
0
11,943
19,836
Prepaid expenses and other current assets
7,430
7,417
5,144
2,914
Total current assets
123,411
25,580
22,896
29,202
Property and equipment, net
506
550
595
616
Operating lease right-of-use assets
0
415
453
481
Intangible assets
0
0
67,819
67,726
Other assets
78
78
1,760
11,874
Total assets
123,995
26,623
93,523
109,899
Accounts payable
4,636
5,392
2,223
3,403
Accrued expenses and other current liabilities
3,864
3,376
10,608
5,121
Current portion of debt
0
0
18,026
17,520
Short-term contingent consideration
0
0
12,369
-
Total current liabilities
8,500
8,768
43,226
26,044
Long-term debt
-
-
0
0
Long-term operating lease liabilities
0
293
330
359
Long-term contingent consideration
0
0
51,961
61,213
Deferred tax liabilities
-
-
0
5,593
Warrant liabilities
6,292
694
32,150
14,853
Other long-term liabilities
716
1,196
1,570
778
Total liabilities
15,508
10,951
129,237
108,840
Series c preferred stock, 0.001 par value, 294,370 shares and no shares designated as of june 30, 2026 and december 31, 2025, respectively 211,301.868 and no shares issued and outstanding as of june 30, 2026 and december 31, 2025, respectively
143,811
-
-
-
Common stock, 0.001 par value, 250,000,000 shares authorized, 1,017,063 and 278,627 shares issued and outstanding as of june 30, 2026 and december 31, 2025, respectively
1
14
55
54
Additional paid in capital
460,447
435,587
418,932
415,705
Accumulated other comprehensive income
4,255
4,610
5,750
6,293
Accumulated deficit
-500,027
-424,539
-460,451
-420,993
Total stockholders' equity (deficit)
-35,324
15,672
-35,714
1,059
Total liabilities, mezzanine equity, and stockholders' equity (deficit)
123,995
26,623
93,523
109,899
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Balance Sheets

Cash and cashequivalents$115,981K (589.30%↑ Y/Y)Prepaid expenses andother current assets$7,430K (181.76%↑ Y/Y)Total current assets$123,411K (230.46%↑ Y/Y)Property and equipment,net$506K (-11.69%↓ Y/Y)Other assets$78K (-99.30%↓ Y/Y)Total assets$123,995K (5.79%↑ Y/Y)Accumulated deficit-$500,027K (-22.69%↓ Y/Y)Total liabilities,mezzanine equity, and...$123,995K (5.79%↑ Y/Y)Total stockholders'equity (deficit)-$35,324K (-400.99%↓ Y/Y)Additional paid in capital$460,447K (11.47%↑ Y/Y)Accumulated othercomprehensive income$4,255K (-30.88%↓ Y/Y)Common stock, 0.001 parvalue, 250,000,000...$1K (-98.11%↓ Y/Y)Series c preferredstock, 0.001 par value,...$143,811K Total liabilities$15,508K (-85.30%↓ Y/Y)Total currentliabilities$8,500K (13.83%↑ Y/Y)Warrant liabilities$6,292K (-58.45%↓ Y/Y)Other long-termliabilities$716K (-3.89%↓ Y/Y)Accounts payable$4,636K (163.56%↑ Y/Y)Accrued expenses andother current...$3,864K (-32.31%↓ Y/Y)

Quince Therapeutics, Inc. (QNCX)

Quince Therapeutics, Inc. (QNCX)